Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
Trial ID or NCT#
NCT03895437
Status
RECRUITING
Purpose
The study is a prospective, randomized, 52-week double-blind, placebo-controlled, multicenter trial in subjects with T1D followed by a 2-year safety follow-up.
Official Title
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset or Established Type 1 Diabetes Mellitus
Eligibility Criteria
Ages Eligible for Study: 12 Years to 40 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Darrell Wilson
Contact us to find out if this trial is right for you.
Contact
Trudy Esrey
650-498-4450
View on ClinicalTrials.gov
